Longevity & AgingFDA Reportedly Expands Ryzumvi Approval to Treat Age-Related Near Vision Loss
Presbyopia, the age-related loss of near focusing ability, may have another prescription treatment option. MedPage Today reports that the FDA expanded approval of phentolamine eye drops, sold as Ryzumvi, to treat the condition. In a trial of 569 adults ages 40–64, 27% using nightly drops gained at least three lines of near vision while maintaining distance vision within the study’s limit, compared with 12% using placebo. The drops reduce pupil size rather than reverse aging of the eye’s lens. Common side effects included redness and irritation. An eye care professional can help determine suitability, especially for contact lens wearers or adults with eye inflammation. Important caveats remain: the report relies partly on company statements, and its headline references twelve weeks while the detailed results describe day eight.
